1/24
05:08 am
indp
Indaptus Therapeutics (NASDAQ:INDP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Indaptus Therapeutics (NASDAQ:INDP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/29
07:00 am
indp
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Medium
Report
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar